Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Clinical evaluation of IFN beta1b in COVID-19 MESHD pneumonia: a retrospective study

    Authors: Miriam Estebanez; German Ramirez-Olivencia; Tatiana Mata; David Marti; Carlos Gutierrez; Begona De Dios; Maria Dolores Herrero; Ana Roel; Yolanda Martinez; Alejandro Aguirre; Francisco Alcantara Nicolas; Pablo Fernandez Gonzalez; Elena Lopez; Lucia E Ballester; Maria Mateo-Maestre; Sergio Campos; Maria J Sanchez-Carrillo; Antonio Fe; Francisco J Membrillo de Novales

    doi:10.1101/2020.05.15.20084293 Date: 2020-05-19 Source: medRxiv

    Background COVID-19 MESHD pneumonia MESHD is associated with significant mortality and has no approved antiviral therapy. Interferon beta1 HGNC has shown in vitro studies a potent inhibition of SARS-CoV MESHD and MERS-CoV. In an in vitro study, SARS-CoV-2 had more sensitivity to IFN-I pretreatment that SARS-CoV MESHD. A combination of IFN beta1b administered subcutaneously with other antiviral treatments has been recommended in several guidelines. However, clinical trial results for the treatment of COVID-19 MESHD are pending. We aimed to assess the efficiency of IFN beta1 HGNCb in COVID19 MESHD comparing the in-hospital mortality between patients who received IFN beta1b and patients did not receive. Methods In this retrospective cohort study, we included hospitalized adults with COVID-19 MESHD between February 23th and April 4th, 2020, at the Central Defense Hospital (Madrid, Spain). Subcutaneous interferon beta-1b HGNC was recommended in moderate-severe pneumonia MESHD. The primary endpoint was in-hospital mortality. Univariate and multivariate analysis was performed to identify variables associated with in-hospital mortality. Findings We analyzed 256 patients (106 patients in interferon group and 150 patients in control group). At admission, patients who did not receive interferon beta1 HGNCb presented a greater number of comorbidities. The overall mortality rate was 24.6% (63/256). Twenty-two patients (20.8%) in the interferon group died and 41 (27.3%) in the control group (p=0.229). In the multivariate analysis, the predictors of in-hospital mortality were age, severity of clinical picture at admission and hydroxychloroquine treatment. Interpretation In hospitalized patients with COVID-19 MESHD, interferon beta1b treatment was not associated to decrease in-hospital mortality. Further assessment of the earlier administration of this drug in randomized trials is recommended.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.